[HTML][HTML] Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study

M Gupta, GBJ Mancini, RJ Wani, V Ahooja, J Bergeron… - CJC open, 2022 - Elsevier
Abstract Background The 2021 Canadian Cardiovascular Society guidelines recommend
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …

Effect of evolocumab in patients with prior percutaneous coronary intervention

RHM Furtado, AA Fagundes Jr, K Oyama… - Circulation …, 2022 - Am Heart Assoc
Background: Patients with prior percutaneous coronary intervention (PCI) are at high
residual risk for multiple types of coronary events within and beyond the stented lesion. This …

LDL-C levels, lipid-lowering treatment and recurrent stroke in minor ischaemic stroke or TIA

Y Pan, R Wangqin, H Li, A Jin, J Li, J Lin… - Stroke and Vascular …, 2022 - svn.bmj.com
Background and purpose Dyslipidaemia is a major risk factor for ischaemic stroke and
transient ischaemic attack (TIA). This study aimed to investigate the association between …

[HTML][HTML] Increasing prevalence and incidence of atherosclerotic cardiovascular disease in adult patients in Ontario, Canada from 2002 to 2018

ES Mackinnon, R Goeree, SG Goodman, RM Rogoza… - CJC open, 2022 - Elsevier
Background Cardiovascular disease is the second-leading cause of death in Canada.
However, limited data are available on the prevalence of atherosclerotic cardiovascular …

Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery …

T Hashimoto, Y Minami, K Asakura, M Katamine… - Journal of Clinical …, 2022 - Elsevier
Background Reducing low-density lipoprotein cholesterol (LDL-C) levels with statins slows
the progression of atherosclerotic plaques and reduces cardiovascular events. The 2019 …

[PDF][PDF] 老年冠心病患者冠状动脉血运重建术后主要不良心血管事件的危险因素分析及风险预测模型的构建

杨明, 刘敏, 聂斌, 程波, 徐亚宁, 姚峰, 刘建华 - 临床内科杂志, 2022 - lcnkzz.com
目的探讨老年冠心病患者冠状动脉血运重建术后主要不良心血管事件(MACE)
的危险因素及干预模式的有效性, 建立并验证风险预测模型. 方法采用区组随机化法, 将200 …

In-Hospital Major Adverse Cardiac Events Factor Predictors on ST-Elevation Myocardial Infarction after Primary Percutaneous Coronary Intervention at dr. Cipto …

SA Nasution, H Perkasa, E Ginanjar… - EJournal Kedokteran …, 2022 - ejki.fk.ui.ac.id
Abstract Major Adverse Cardiac Events (MACE) are the main causes to increase mortality in
ST-Elevation Myocardial Infarction (STEMI) patients who undergo Primary Percutaneous …

Low-density lipoprotein cholesterol and mortality risk in elderly patients undergoing valve replacement surgery: a propensity score matching analysis

H Li, B Fu, T Tan, X Li, S Wang, X Wei, Z Wang - Frontiers in Nutrition, 2022 - frontiersin.org
Background The prognostic value of low-density lipoprotein cholesterol (LDL-C) in elderly
patients is controversial. This study aimed to elucidate the relationship between the …

[HTML][HTML] 早发急性ST 段抬高型心肌梗死患者预后风险列线图模型的构建与验证

张鑫, 丁莹, 姚毅仁, 谷阳, 张喜文 - 南京医科大学学报(自然科学 …, 2022 - jnmu.njmu.edu.cn
目的: 分析早发ST 段抬高型心肌梗死(ST-segment elevated myocardial infarction, STEMI)
患者的危险因素, 并建立预测早发STEMI 患者术后主要心血管不良事件(major adverse cardiac …

[HTML][HTML] Low-Density Lipoprotein Cholesterol Treatment Target Achievement in Patients with Myocardial Infarction, Percutaneous Coronary Intervention, or Stroke in …

JE Blais, VKC Yan, J Zhao, CSL Chui… - Reviews in …, 2022 - imrpress.com
Background: Elevated concentrations of low-density lipoprotein cholesterol (LDL-C) are an
important cause of recurrent cardiovascular events. This study aimed to describe the …